<bill session="116" type="s" number="3133" updated="2022-10-28T01:46:13Z">
  <state datetime="2019-12-19">REFERRED</state>
  <status>
    <introduced datetime="2019-12-19"/>
  </status>
  <introduced datetime="2019-12-19"/>
  <titles>
    <title type="display">Conditional Approval Act</title>
    <title type="short" as="introduced">Conditional Approval Act</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="B001310"/>
  <cosponsors>
    <cosponsor bioguide_id="M001153" joined="2020-01-14"/>
  </cosponsors>
  <actions>
    <action datetime="2019-12-19">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-12-19" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="5497" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Civil actions and liability"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Health care coverage and access"/>
    <term name="Health information and medical records"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-03T15:17:45Z" status="Introduced in Senate">Conditional Approval Act

This bill authorizes the Food and Drug Administration to conditionally approve certain new drugs intended for diseases that are seriously debilitating, life threatening, or chronic, and for which meaningful treatments do not exist. The bill also limits liability related to these conditionally approved drugs.</summary>
</bill>
